| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/JM030383M |
| P8608 | Fatcat ID | release_ocq6sq32ufejfgc2j525kjdn5m |
| P698 | PubMed publication ID | 14998334 |
| P5875 | ResearchGate publication ID | 6762618 |
| P50 | author | Carolyn J. Anderson | Q50419498 |
| Charles Boswell | Q73389295 | ||
| Weijun Niu | Q125341858 | ||
| Arnold L. Rheingold | Q4795140 | ||
| P2093 | author name string | Xiankai Sun | |
| Edward H Wong | |||
| Gary R Weisman | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | copper | Q753 |
| P304 | page(s) | 1465-1474 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes | |
| P478 | volume | 47 |
| Q33956262 | (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer |
| Q37218456 | (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity |
| Q39379613 | 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas |
| Q35777600 | 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy |
| Q38815325 | 64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor |
| Q64980444 | 64Cu-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases. |
| Q88079319 | 64Cu-Labeled multifunctional dendrimers for targeted tumor PET imaging |
| Q42756624 | 64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model |
| Q37088807 | 64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics |
| Q34140651 | 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors |
| Q34083332 | 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression |
| Q35141767 | 64Cu-labeled lissamine rhodamine B: a promising PET radiotracer targeting tumor mitochondria |
| Q35169192 | 64Cu-labeled phosphonium cations as PET radiotracers for tumor imaging |
| Q34665668 | 64Cu-labeled somatostatin analogues conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studies |
| Q39729101 | A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection |
| Q35650526 | A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. |
| Q38900380 | A dual radiolabelling approach for tracking metal complexes: investigating the speciation of copper bis(thiosemicarbazonates) in vitro and in vivo |
| Q33616878 | A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors |
| Q40095056 | A new PET tracer specific for vascular endothelial growth factor receptor 2. |
| Q38985097 | A novel Affibody bioconjugate for dual-modality imaging of ovarian cancer |
| Q42576154 | A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging |
| Q37085287 | A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imaging |
| Q37213034 | A novel technology for the imaging of acidic prostate tumors by positron emission tomography |
| Q36908712 | A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies |
| Q57181636 | Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of Nanoparticles |
| Q33369095 | An optimized, chemically regulated gene expression system for Chlamydomonas |
| Q40182879 | Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? |
| Q38944485 | Bifunctional (64)Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography |
| Q24649091 | Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides |
| Q34591066 | Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe--feasibility study in rat model |
| Q42419241 | Biocompatible nanocomposite for PET/MRI hybrid imaging |
| Q37924117 | Bisphosphonates as radionuclide carriers for imaging or systemic therapy. |
| Q39297457 | CXCR4 chemokine receptor antagonists: nickel(II) complexes of configurationally restricted macrocycles |
| Q24619854 | Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats |
| Q41481562 | Chelator-Free Radiolabeling of SERRS Nanoparticles for Whole-Body PET and Intraoperative Raman Imaging |
| Q38172069 | Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals |
| Q39579062 | Combined Positron Emission Tomography and Cerenkov Luminescence Imaging of Sentinel Lymph Nodes Using PEGylated Radionuclide-Embedded Gold Nanoparticles |
| Q53676991 | Comparative Assessment of Complex Stabilities of Radiocopper Chelating Agents by a Combination of Complex Challenge and in vivo Experiments. |
| Q34049108 | Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer |
| Q27339846 | Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability |
| Q39692454 | Comparison of bifunctional chelates for (64)Cu antibody imaging |
| Q43146841 | Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors |
| Q33870879 | Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease |
| Q46924077 | Coordination Chemistry of Bifunctional Chemical Agents Designed for Applications in 64Cu PET Imaging for Alzheimer's Disease |
| Q35994738 | Copper(II) cyclam-based complexes for radiopharmaceutical applications: synthesis and structural analysis |
| Q37126530 | Copper-64 Radiopharmaceuticals for Oncologic Imaging |
| Q36315404 | Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development |
| Q37478003 | Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research |
| Q45986152 | Copper-64-alloyed gold nanoparticles for cancer imaging: improved radiolabel stability and diagnostic accuracy. |
| Q92925250 | Copper-Bispidine Complexes: Synthesis and Complex Stability Study |
| Q34866598 | Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. |
| Q34291386 | Crystal structures of two cross-bridged chromium(III) tetra-aza-macrocycles. |
| Q37545575 | Cu(I)-assisted click chemistry strategy for conjugation of non-protected cross-bridged macrocyclic chelators to tumour-targeting peptides. |
| Q46452997 | Cyclen derivatives with two trans-methylnitrophenolic pendant arms: a structural study of their copper(II) and zinc(II) complexes. |
| Q39255701 | Cyclization of RGD peptide sequences via the macrocyclic chelator DOTA for integrin imaging. |
| Q36690711 | Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry |
| Q41656026 | Design and Modular Construction of a Polymeric Nanoparticle for Targeted Atherosclerosis Positron Emission Tomography Imaging: A Story of 25% (64)Cu-CANF-Comb |
| Q92676561 | Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide |
| Q36394415 | Development of copper based drugs, radiopharmaceuticals and medical materials. |
| Q46321334 | Development of multi-functional chelators based on sarcophagine cages. |
| Q33301860 | Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. |
| Q37120903 | Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology |
| Q37722948 | Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticals |
| Q33832487 | Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature |
| Q47105084 | Evaluation of 64Cu-Based Radiopharmaceuticals that Target Aβ Peptide Aggregates as Diagnostic Tools for Alzheimer's Disease. |
| Q34906397 | Evaluation of 64Cu-labeled acridinium cation: a PET radiotracer targeting tumor mitochondria |
| Q34870617 | Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide |
| Q30497061 | Fast 18F Labeling of a Near-Infrared Fluorophore Enables Positron Emission Tomography and Optical Imaging of Sentinel Lymph Nodes |
| Q36673486 | Fibrin-targeted PET probes for the detection of thrombi |
| Q36191589 | First-in-human uPAR PET: Imaging of Cancer Aggressiveness |
| Q36580750 | Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. |
| Q37142624 | H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu |
| Q37412579 | H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. |
| Q21132365 | Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine |
| Q34555450 | Human umbilical cord plasma proteins revitalize hippocampal function in aged mice |
| Q35161921 | Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. |
| Q34992753 | Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies |
| Q37375024 | In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors |
| Q34942281 | In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer |
| Q35925945 | In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer |
| Q34519479 | In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. |
| Q33916932 | In vivo molecular imaging of thrombosis and thrombolysis using a fibrin-binding positron emission tomographic probe |
| Q34231627 | In vivo targeting of HER2-positive tumor using 2-helix affibody molecules |
| Q92942042 | Innovative Magnetic Nanoparticles for PET/MRI Bimodal Imaging |
| Q39244136 | Intrinsically copper-64-labeled organic nanoparticles as radiotracers |
| Q34315359 | Intrinsically radiolabeled nanoparticles: an emerging paradigm |
| Q42084619 | Isomeric trimethylene and ethylene pendant-armed cross-bridged tetraazamacrocycles and in vitro/in vivo comparisions of their copper(II) complexes |
| Q34144898 | Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects. |
| Q34995512 | Macrocyclic chelator assembled RGD multimers for tumor targeting |
| Q33480211 | Macrocyclic diamide ligand systems: potential chelators for 64Cu- and 68Ga-based positron emission tomography imaging agents |
| Q38156660 | Matching chelators to radiometals for radiopharmaceuticals |
| Q31116849 | Metal complexes of cyclen and cyclam derivatives useful for medical applications: a discussion based on thermodynamic stability constants and structural data |
| Q88629120 | Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors |
| Q33867550 | Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography |
| Q37356557 | Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). |
| Q36197970 | Molecular imaging probe development: a chemistry perspective. |
| Q36044493 | Molecular targeting of CEACAM6 using antibody probes of different sizes |
| Q48554795 | Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT. |
| Q39065411 | Nanogels from metal-chelating crosslinkers as versatile platforms applied to copper-64 PET imaging of tumors and metastases |
| Q42173095 | New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. |
| Q52990593 | New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative. |
| Q33636030 | Non-cross-bridged tetraazamacrocyclic chelator for stable (64)cu-based radiopharmaceuticals |
| Q40031313 | Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor |
| Q28478106 | Non-invasive imaging of cysteine cathepsin activity in solid tumors using a 64Cu-labeled activity-based probe |
| Q37263864 | Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide |
| Q38729299 | Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents |
| Q34072844 | Novel hexadentate and pentadentate chelators for ⁶⁴Cu-based targeted PET imaging |
| Q34698624 | Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine |
| Q37114971 | On-demand drug release system for in vivo cancer treatment through self-assembled magnetic nanoparticles |
| Q36383722 | Optical imaging of tumors with copper-labeled rhodamine derivatives by targeting mitochondria |
| Q92722219 | Optimization of Hexadentate Bispidine Ligands as Chelators for 64 CuII PET Imaging |
| Q42876685 | Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7–14)NH2], in a prostate tumor xenografted mouse model |
| Q34895626 | PET imaging of CXCR4 using copper-64 labeled peptide antagonist |
| Q33939881 | PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. |
| Q39066068 | PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate |
| Q48278064 | PET imaging with copper-64 as a tool for real-time in vivo investigations of the necessity for cross-linking of polymeric micelles in nanomedicine |
| Q28546012 | PET/CT Based In Vivo Evaluation of 64Cu Labelled Nanodiscs in Tumor Bearing Mice |
| Q48625690 | Peptide-based fibrin-targeting probes for thrombus imaging |
| Q38149131 | Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers |
| Q36337218 | Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. |
| Q36578038 | Phospholipids showing complex bilayer phase transitions. II. Four sulfur-containing phosphatidylcholines |
| Q52859832 | Polyglycerol-Based Copper Chelators for the Transport and Release of Copper Ions in Biological Environments. |
| Q30480648 | Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates |
| Q28741667 | Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA |
| Q36557471 | Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments |
| Q30836426 | Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100 |
| Q34677178 | Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator |
| Q37479595 | Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors |
| Q28829134 | Pretargeted Positron Emission Tomography Imaging That Employs Supramolecular Nanoparticles with in Vivo Bioorthogonal Chemistry |
| Q37424123 | Promising bifunctional chelators for copper 64-PET imaging: practical (64)Cu radiolabeling and high in vitro and in vivo complex stability |
| Q33593443 | Pycup--a bifunctional, cage-like ligand for (64)Cu radiolabeling |
| Q36934661 | QSAR studies of copper azamacrocycles and thiosemicarbazones: MM3 parameter development and prediction of biological properties. |
| Q39941113 | Quantitative PET imaging of VEGF receptor expression |
| Q38166986 | RGD-based PET tracers for imaging receptor integrin αv β3 expression |
| Q38196380 | Radiocopper for the imaging of copper metabolism |
| Q37689802 | Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy |
| Q38088748 | Radiolabeled peptide-receptor ligands in tumor imaging. |
| Q80093411 | Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64 |
| Q36622418 | Radioluminescent gold nanocages with controlled radioactivity for real-time in vivo imaging |
| Q37847064 | Radiometallated peptides for molecular imaging and targeted therapy. |
| Q38273277 | Radiometals: towards a new success story in nuclear imaging? |
| Q55074250 | Recent developments in multimodality fluorescence imaging probes. |
| Q37515337 | Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods |
| Q35537978 | Silica nanoparticles as substrates for chelator-free labeling of oxophilic radioisotopes. |
| Q34134418 | Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog |
| Q37592073 | Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models |
| Q38120755 | Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist |
| Q33699158 | Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer |
| Q35565660 | Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes. |
| Q92477543 | Synthesis and evaluation of 64Cu-radiolabeled NOTA-cetuximab (64Cu-NOTA-C225) for immuno-PET imaging of EGFR expression |
| Q33700114 | Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer |
| Q38334449 | Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging |
| Q38848237 | Synthesis and structural studies of two pyridine-armed reinforced cyclen chelators and their transition metal complexes. |
| Q36892360 | Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging |
| Q36826058 | Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling. |
| Q36291655 | Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms |
| Q50848539 | Synthesis, characterisation and evaluation of a novel copper-64 complex with selective uptake in EMT-6 cells under hypoxic conditions. |
| Q40043661 | Synthesis, in vitro and in vivo characterization of (64)Cu(I) complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands. |
| Q53541823 | Synthesis, structural studies, kinetic stability, and oxidation catalysis of the late first row transition metal complexes of 4,10-dimethyl-1,4,7,10-tetraazabicyclo[6.5.2]pentadecane. |
| Q28066010 | Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy |
| Q27322455 | T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment |
| Q37790065 | Target-specific delivery of peptide-based probes for PET imaging |
| Q39565634 | Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases |
| Q38570145 | The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. |
| Q51596074 | The computation of lipophilicities of ⁶⁴Cu PET systems based on a novel approach for fluctuating charges. |
| Q36052972 | The efficient synthesis and biological evaluation of novel bi-functionalized sarcophagine for (64)cu radiopharmaceuticals |
| Q34901742 | The long and short of it: the influence of N-carboxyethyl versusN-carboxymethyl pendant arms on in vitro and in vivo behavior of copper complexes of cross-bridged tetraamine macrocycles |
| Q37812509 | The significance of copper chelators in clinical and experimental application |
| Q39162754 | The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents |
| Q38080002 | The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging |
| Q39015694 | Theranostics of malignant melanoma with 64CuCl2. |
| Q40039814 | Towards Translational ImmunoPET/MR Imaging of Invasive Pulmonary Aspergillosis: The Humanised Monoclonal Antibody JF5 Detects Aspergillus Lung Infections In Vivo. |
| Q36372777 | Transferrin conjugates of triazacyclononane-based bifunctional NE3TA chelates for PET imaging: Synthesis, Cu-64 radiolabeling, and in vitro and in vivo evaluation. |
| Q88988634 | Tumor Theranostics of Transition Metal Ions Loaded Polyaminopyrrole Nanoparticles |
| Q52318963 | Understanding the In Vivo Fate of Radioimmunoconjugates for PET and SPECT. |
| Q28834080 | Universal Molecular Scaffold for Facile Construction of Multivalent and Multimodal Imaging Probes |
| Q26865306 | Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications |
| Q40475702 | VPAC1 Targeted 64Cu-TP3805 kit preparation and its evaluation. |
| Q41845074 | What a difference a carbon makes: H₄octapa vs H₄C3octapa, ligands for In-111 and Lu-177 radiochemistry |
| Q39371008 | Zinc(II) complexes of constrained antiviral macrocycles. |
| Q37718007 | Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. |
| Q35881049 | [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues |
| Q59602628 | [Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model |
| Q54239367 | trans-Methylpyridine cyclen versus cross-bridged trans-methylpyridine cyclen. Synthesis, acid-base and metal complexation studies (metal = Co2+, Cu2+, and Zn2+). |
| Q38705627 | ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer |
Search more.